Die medikamentöse Therapie des HCC mit Sorafenib – der Beginn einer neuen Ära in der Behandlung des HCC

 

 Buy Article Permissions and Reprints

Zusammenfassung

Seit 2007 steht mit Sorafenib erstmals eine wirksame Therapie für Patienten mit einem HCC zur Verfügung, die zu einer Verlängerung des mittleren Überlebens von fast 3 Monaten geführt hat. Trotzdem bleibt auch bei dieser Therapie das mittlere Gesamtüberleben für Patienten mit einem fortgeschrittenen HCC unter 1 Jahr. Basierend auf Untersuchungen zur molekularen Karzinogenese einerseits, und andererseits der Entwicklung von neuen molekularen Therapien in anderen Indikationen und Ergebnissen von Biomarkeruntersuchungen bei Patienten mit HCC unter Therapie, werden derzeit neue Therapiestrategien zur Behandlung des HCC im Rahmen von klinischen Studien evaluiert. Im Folgenden fassen wir die aktuellen Kenntnisse zur molekularen Therapie des HCC zusammen und zeigen Wege auf, wie neue Substanzen effektiv in der Indikation des HCC evaluiert werden können.

Abstract

Sorafenib increases overall survival in patients with advanced HCC by almost three months. However, despite these advances in the treatment of patients with HCC, average overall survival remains below one year. Based on our understanding of hepatocarcinogenesis, the development of new molecular targeting agents and results from biomarker studies in HCC, new therapeutic treatment options are currently being investigated. We summarize recent results on the molecular therapy for HCC and discuss how these can be efficiently tested in patients with HCC.

Literatur

• 1 Ferlay J, Autier P, Boniol M. et al . Estimates of the cancer incidence and mortality in Europe in 2006.  Ann Oncol. 2007;  18 581-592
  Google Scholar
• 2 Greten T F, Wedemeyer H, Manns M P. Prävention Virus-assoziierter Karzinomentstehung: Am Beispiel des hepatozellulären Karzinoms.  Deutsches Ärzteblatt. 2006;  103 A-1817
  Google Scholar
• 3 Jemal A, Siegel R, Ward E. et al . Cancer statistics, 2007.  CA Cancer J Clin. 2007;  57 43-66
  Google Scholar
• 4 Greten T F, Papendorf F, Bleck J S. et al . Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients.  Br J Cancer. 2005;  92 1862-1868
  Google Scholar
• 5 Greten T F, Blum H E, Manns M P. et al . Therapie des hepatozellulären Karzinoms.  Z Gastroenterol. 2006;  44 43-49
  Google Scholar
• 6 Escudier B, Eisen T, Stadler W M. et al . Sorafenib in advanced clear-cell renal-cell carcinoma.  N Engl J Med. 2007;  356 125-134
  Google Scholar
• 7 Strumberg D, Clark J W, Awada A. et al . Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.  Oncologist. 2007;  12 426-437
  Google Scholar
• 8 Llovet J M, Ricci S, Mazzaferro V. et al . Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med. 2008;  359 378-390
  Google Scholar
• 9 Pang R W, Poon R T. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.  Oncology. 2007;  72 (Suppl 1) 30-44
  Google Scholar
• 10 Zhu A X, Blaszkowsky L S, Ryan D P. et al . Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.  J Clin Oncol. 2006;  24 1898-1903
  Google Scholar
• 11 Thomas M B, Chadha R, Iwasaki M. et al . The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2007;  25 4567
  Google Scholar
• 12 Zhu A X, Sahani D V, Tomaso di E. et al . A phase II study of sunitinib in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2007;  25 4637
  Google Scholar
• 13 Koch I, Baron A, Roberts S. et al . Influence of Hepatic Dysfunction on Safety, Tolerability, and Pharmacokinetics (PK) of PTK787 /ZK 222 584 in Patients with Unresectable Hepatocellular Carcinoma.  J Clin Oncol. 2005;  23 4134
  Google Scholar
• 14 Drevs J, Siegert P, Medinger M. et al . Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.  J Clin Oncol. 2007;  25 3045-3054
  Google Scholar
• 15 Podar K, Tonon G, Sattler M. et al . The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.  Proc Natl Acad Sci USA. 2006;  103 19 478-19 483
  Google Scholar
• 16 Thomas M B, Chadha R, Glover K. et al . Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.  Cancer. 2007;  110 1059-1067
  Google Scholar
• 17 Semela D, Piguet A C, Kolev M. et al . Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.  J Hepatol. 2007;  46 840-848
  Google Scholar
• 18 Knight B, Tirnitz-Parker J E, Olynyk J K. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.  Gastroenterology. 2008;  135 979 e961
  Google Scholar
• 19 Eckel F, Delius von S, Mayr M. et al . Pharmacokinetic and clinical phase ii trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.  Oncology. 2005;  69 363-371
  Google Scholar
• 20 Lin A Y, Fisher G A, So S. et al . Phase II study of imatinib in unresectable hepatocellular carcinoma.  Am J Clin Oncol. 2008;  31 84-88
  Google Scholar
• 21 Wang Z, Zhou J, Fan J. et al . Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.  Clin Cancer Res. 2008;  14 5124-5130
  Google Scholar
• 22 Pena C, Shan M, Wilhelm S. et al . Hepatocyte growth factor (HGF) is a prognostic biomarker for overall survival and a pharmacodynamic biomarker of sorafenib response in the SHARP III HCC trials.  Annals of Oncology. 2008;  19 (Suppl 8) viii153-viii165
  Google Scholar
• 23 Llovet J M, Di Bisceglie A M, Bruix J. et al . Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma.  J Natl Cancer Inst. 2008;  100 698-711
  Google Scholar
• 24 Kanai F, Yoshida H, Teratani T. et al . New feasibility study design with hepatocellular carcinoma: A phase I/II study of TSU-68, an oral angiogenesis inhibitor.  J Clin Oncol. 2006;  24 4145
  Google Scholar
• 25 Siegel A B, Cohen E I, Ocean A. et al . Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.  J Clin Oncol. 2008;  26 2992-2998
  Google Scholar
• 26 Malka D, Dromain C, Farace F. et al . Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring.  J Clin Oncol. 2007;  25 4570
  Google Scholar
• 27 Sun W, Haller D G, Mykulowycz K. et al . Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study.  J Clin Oncol. 2007;  25 4574
  Google Scholar
• 28 Hsu C, Yang T, Hsu C. et al . Modified-dose capecitabine+bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study.  J Clin Oncol. 2007;  25 15 190
  Google Scholar
• 29 Faivre S J, Raymond E, Douillard J. et al . Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC).  J Clin Oncol. 2007;  25 3546
  Google Scholar
• 30 Hoda D, Catherine C, Strosberg J. et al .Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium Orlando; 2008
  Google Scholar
• 31 Philip P A, Mahoney M R, Allmer C. et al . Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.  J Clin Oncol. 2005;  23 6657-6663
  Google Scholar
• 32 O’Dwyer P J, Giantonio B J, Levy D E. et al . Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E 1203.  J Clin Oncol. 2006;  24 4143
  Google Scholar
• 33 Ramanathan R K, Belani C P, Singh D A. et al . Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2 /Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial.  J Clin Oncol. 2006;  24 4010
  Google Scholar
• 34 Zhu A X, Stuart K, Blaszkowsky L S. et al . Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.  Cancer. 2007;  110 581-589
  Google Scholar
• 35 Grunwald V, Wilkens L, Gebel M. et al . A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results.  J Clin Oncol. 2007;  25 4598
  Google Scholar
• 36 Louafi S, Hebbar M, Rosmorduc O. et al . Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO.  J Clin Oncol. 2007;  25 4594
  Google Scholar
• 37 O’Neil B H, Bernard S A, Goldberg R M. et al . Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma.  J Clin Oncol. 2008;  26 4604
  Google Scholar
• 38 Greten T F, Korangy F, Manns M P. et al . Molecular therapy for the treatment of hepatocellular carcinoma.  Br J Cancer. 2008 [in press]; 
  Google Scholar

Prof. Dr. Tim Greten

Gastroenterologie, Hepatologie, Endokrinologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Phone: 05 11/5 32 73 11

Fax: 05 11/5 32 20 21

Email: greten.tim@mh-hannover.de